Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals, Inc. (AVIR)
:AVIR
Total Valuation
Atea Pharmaceuticals has a market cap or net worth of $275.57M. The enterprise value is $2.48B.
Market Cap$275.57M
Enterprise Value$2.48B
Share Statistics
Atea Pharmaceuticals has 85,579,475 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding85,579,475
Owned by Insiders9.30%
Owned by Institutions21.28%
Financial Efficiency
Atea Pharmaceuticals’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -43.42%.
Return on Equity (ROE)-0.38
Return on Assets (ROA)-0.36
Return on Invested Capital (ROIC)-43.42%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee0.00
Profits Per Employee-3.01M
Employee Count56
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Atea Pharmaceuticals is -1.68. Atea Pharmaceuticals’s PEG ratio is 0.02.
PE Ratio-1.68
PS Ratio0.00
PB Ratio0.63
Price to Fair Value0.64
Price to FCF-3.26
Price to Operating Cash Flow-3.31
PEG Ratio0.02
Income Statement
In the last 12 months, Atea Pharmaceuticals had revenue of 0.00 and earned -168.38M in profits. Earnings per share was -2.00.
Revenue0.00
Gross Profit0.00
Operating Income-192.95M
Pretax Income-167.46M
Net Income-168.38M
EBITDA-167.04M
Earnings Per Share (EPS)-2.00
Cash Flow
In the last 12 months, operating cash flow was -126.20M and capital expenditures 0.00, giving a free cash flow of -126.20M billion.
Operating Cash Flow-126.20M
Free Cash Flow-126.20M
Free Cash Flow per Share-1.47
Dividends & Yields
Atea Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.61
52-Week Price Change-14.05%
50-Day Moving Average2.90
200-Day Moving Average3.21
Relative Strength Index (RSI)61.46
Average Volume (3m)438.53K
Important Dates
Atea Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Atea Pharmaceuticals as a current ratio of 24.85, with Debt / Equity ratio of 0.49%
Current Ratio24.85
Quick Ratio24.85
Debt to Market Cap<0.01
Net Debt to EBITDA0.38
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Atea Pharmaceuticals has paid 925.00K in taxes.
Income Tax925.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Atea Pharmaceuticals EV to EBITDA ratio is -1.31, with an EV/FCF ratio of -1.62.
EV to Sales0.00
EV to EBITDA-1.31
EV to Free Cash Flow-1.62
EV to Operating Cash Flow-1.62
Balance Sheet
Atea Pharmaceuticals has $425.44M in cash and marketable securities with $1.45M in debt, giving a net cash position of -$423.99M billion.
Cash & Marketable Securities$425.44M
Total Debt$1.45M
Net Cash-$423.99M
Net Cash Per Share-$4.95
Tangible Book Value Per Share$5.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Atea Pharmaceuticals is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside86.34% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-22.66%